Compounds > raloxifene hydrochloride
Page last updated: 2024-08-23

raloxifene hydrochloride and fenretinide

raloxifene hydrochloride has been researched along with fenretinide in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (88.89)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J1
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J1
Carolin, KA; Pass, HA1
Zujewski, J1
Kahán, Z; Thurzó, L1
Bonanni, B; Cazzaniga, M; Decensi, A; Galli, A; Gonzaga, AG; Serrano, D1
Costa, A; Decensi, A; Perego, E; Serrano, D1
Temin, S1
Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H1

Reviews

6 review(s) available for raloxifene hydrochloride and fenretinide

ArticleYear
Prevention of breast cancer.
    Critical reviews in oncology/hematology, 2000, Volume: 33, Issue:3

    Topics: Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Biological Products; Breast Neoplasms; Breast Neoplasms, Male; Carotenoids; Cathepsin D; Cell Adhesion Molecules; Cell Cycle; Clinical Trials, Phase III as Topic; Drug Screening Assays, Antitumor; Estrogens, Non-Steroidal; Female; Fenretinide; Genetic Predisposition to Disease; Hormone Antagonists; Humans; Isoflavones; Male; Mammary Neoplasms, Experimental; Mastectomy; Mice; Middle Aged; Neovascularization, Pathologic; Ovariectomy; Phytoestrogens; Plant Preparations; Raloxifene Hydrochloride; Rats; Retinoids; Risk Assessment; Risk Factors; Selenium; Tamoxifen; Terpenes

2000
Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.
    Environmental and molecular mutagenesis, 2002, Volume: 39, Issue:2-3

    Topics: Antineoplastic Agents; Breast Neoplasms; Female; Fenretinide; Humans; Incidence; Insulin-Like Growth Factor I; Multicenter Studies as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen

2002
[Breakthrough in breast cancer chemoprevention].
    Orvosi hetilap, 2003, Mar-30, Volume: 144, Issue:13

    Topics: Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Fenretinide; Genes, BRCA1; Genes, BRCA2; Humans; Insulin-Like Growth Factor I; Menopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Time Factors

2003
Pharmacological prevention of breast cancer: quo vadis?
    Breast (Edinburgh, Scotland), 2003, Volume: 12, Issue:6

    Topics: Anticarcinogenic Agents; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Fenretinide; Humans; Raloxifene Hydrochloride; Tamoxifen

2003
Progress in chemoprevention of breast cancer.
    Critical reviews in oncology/hematology, 2004, Volume: 49, Issue:2

    Topics: Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Female; Fenretinide; Hormone Replacement Therapy; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen

2004
Preventive therapy for breast cancer: a consensus statement.
    The Lancet. Oncology, 2011, Volume: 12, Issue:5

    Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles

2011

Other Studies

3 other study(ies) available for raloxifene hydrochloride and fenretinide

ArticleYear
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells

2007
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
    Nature chemical biology, 2009, Volume: 5, Issue:10

    Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection

2009
American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
    Gynecologic oncology, 2009, Volume: 115, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fenretinide; Humans; Raloxifene Hydrochloride; Tamoxifen

2009